European Commission Approves ATRIPLA(R) (efavirenz 600 mg - Press ...
17 Dec 2007 ... The marketing authorisation application for ATRIPLA in the European ... including its updated Research & Development guidance of a range from .... those
identified in Bristol-Myers Squibb's Annual Report on Form 10-K for ...
http://www.gilead.com/pr_1087952...
|
Efavirenz in the therapy of HIV infection.
EFV is the only antiretroviral agent currently on the market that has ... Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.;
Review ...
http://www.ncbi.nlm.nih.gov/pubmed/20001610...
|
Press Releases: Gilead
Efavirenz is available only by prescription and is used in combination with other medicines to treat people ... Merck & Co., Inc. is a global research-
driven pharmaceutical products company. ... market position, product development
and business strategy. ... 2003, and in periodic reports on Form 10-Q and Form 8
-K. ...
http://www.gilead.com/pr_571762...
|
New Data on ISENTRESS® (raltegravir) Presented at the - Merck News ...
17 Feb 2010 ... containing ISENTRESS vs the regimen containing efavirenz (55 percent vs. ... and clinical director of the Aaron Diamond AIDS Research Center in New York.
.... Merck's ability to accurately predict future market conditions; ... 2008
Annual Report on Form 10-K, Schering-Plough's Quarterly Report ...
http://www.merck.com/newsroom/news-release-archive/product/2...
|
Press Releases: Gilead
Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ ..... discovered through a collaborative research effort between Dr. Antonin
Holy, ... 2005 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb
...
http://www.gilead.com/pr_913213...
|
US Department of Health & Human Services Recommends - Merck News Item
1 Dec 2009 ... a working group of the Office of AIDS Research Advisory Council, ... ISENTRESS and efavirenz were administered in combination with tenofovir/
emtricitabine. .... Merck's ability to accurately predict future market
conditions; ... 2008 Annual Report on Form 10-K, Schering-Plough's Quarterly
Report ...
http://www.merck.com/newsroom/news-release-archive/product/2...
|
Press Releases: Gilead
... Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV ... On August 2, the FDA granted marketing approval of Truvada
(TM) .... The company has seven marketed products, and focuses its research and
... Risks are described in detail in the Gilead Annual Report on Form 10-K for
the ...
http://www.gilead.com/pr_607254...
|
Merck News Item
20 Jul 2009 ... soon regarding an expanded marketing authorisation of ISENTRESS in the European ... Results were comparable for patients taking the efavirenz-based
regimen, ... Merck & Co., Inc., is a global research-driven pharmaceutical
company ... periodic reports on Form 10-Q or current reports on Form 8-K, ...
http://www.merck.com/newsroom/news-release-archive/product/2...
|
Corporate Overview: Gilead
Gilead Sciences, Inc. is a research-based biopharmaceutical company that ... number of category firsts and market leaders, including Atripla® (efavirenz 600
...
http://www.gilead.com/corporate_overview...
|
Improving Access in the Developing World and Emerging Markets
15 Sep 2009 ... In addition, Merck has a long history of both in-house research and external ... We support these mechanisms, as well as Advance Market Commitments, .... 1
Efavirenz is marketed by Bristol-Myers Squibb as Sustiva in the United ... 2008
Corporate Responsibility Report · Frequently Asked Questions ...
http://www.merck.com/corporate-responsibility/access/access-...
|
